Keyphrases
Angiotensin Receptor Blockers
22%
Angiotensin-converting Enzyme Inhibitor (ACEi)
22%
Between-group Difference
11%
Dose Change
22%
Drug Therapy
100%
Early Improvement
11%
Enalapril
11%
Entresto
100%
Heart Failure
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
33%
Kansas City Cardiomyopathy Questionnaire
77%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
11%
National Network
11%
Odds Ratio
22%
PARADIGM-HF
11%
Patient-centered Outcomes Research
11%
Patient-reported Outcomes
100%
Propensity Score Weighting
11%
Quality of Life Changes
22%
Quality of Life Improvement
22%
Questionnaire Data
11%
Responder Analysis
11%
Routine Clinical Practice
11%
Sacubitril-valsartan
100%
Nursing and Health Professions
Angiotensin Receptor Antagonist
22%
Brain Natriuretic Peptide
11%
Clinical Practice
11%
Congestive Heart Failure
100%
Dipeptidyl Carboxypeptidase Inhibitor
22%
Drug Therapy
100%
Enalapril
11%
Heart Failure with Reduced Ejection Fraction
33%
Myocardial Disease
77%
Odds Ratio
22%
Outcomes Research
11%
Outpatient
11%
Patient-Reported Outcome
100%
Propensity Score
11%
Quality of Life
44%
Real-World Evidence
11%
Sacubitril Plus Valsartan
100%
Valsartan/Sacubitril
100%
Pharmacology, Toxicology and Pharmaceutical Science
Angiotensin Receptor Antagonist
22%
Brain Natriuretic Peptide
11%
Congestive Heart Failure
100%
Dipeptidyl Carboxypeptidase Inhibitor
22%
Enalapril
11%
Heart Failure with Reduced Ejection Fraction
33%
Myocardial Disease
77%
Pharmacotherapy
100%
Prospective Study
11%
Sacubitril Plus Valsartan
100%
Valsartan/Sacubitril
100%